TABLE 2.
Overview of prevalence of cognitive impairment at different breast cancer treatment stages
| Treatment stage | Prevalence of cognitive impairments (total sum of patients) | Treatment group | Prevalence of cognitive impairments (total sum of patients per treatment group) |
|---|---|---|---|
| Baseline (T0) | 25% (503) | CT | 24% (446) |
| No‐CT | 30% (57) | ||
| Controls | 10% (120) | ||
| After treatment (T1) | 24% (295) | CT | 30% (229) |
| No‐CT | 3% (66) | ||
| Controls | 10% (102) | ||
| Short‐term FU (T2) | 21% (479) | CT | 23% (336) |
| No‐CT | 18% (143) | ||
| Controls | 7% (149) |
Note: The “CT‐group” consists of patients indicated for chemotherapy and if necessary, radiotherapy and/or endocrine therapy. The “no‐CT grou” consists of patients indicated for radiotherapy and/or endocrine therapy.
Abbreviations: CT, chemotherapy; long‐term FU, follow‐up of at least 1 year after treatment completion; short‐term FU, follow‐up of a maximum of 1 year after treatment completion, no‐CT, endocrine and/or radiotherapy.